Janssen Pharmaceutica N.V. Promises Lung Cancer Drug Initiative In China

Janssen Pharmaceutica, an R&D arm of Johnson & Johnson, plans to increase its investment in China to develop new drugs for lung disease, especially cancer. The company said it would launch the new drugs in China first, then expand their reach to the rest of the world. The parent, J&J, will establish a global R&D center in China to further the work. Over the next five years, Janssen plans to launch more than ten new pharmaceutical products and expand its offerings in 50 existing medicines.

Back to news